Fri, Sep 19, 2014, 10:24 AM EDT - U.S. Markets close in 5 hrs 36 mins

Recent

% | $
Quotes you view appear here for quick access.

SIGA Technologies, Inc. Message Board

beavertail_splash 335 posts  |  Last Activity: 19 hours ago Member since: Apr 13, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    200k block of shares dumped

    by hairypotter9 19 hours ago
    beavertail_splash beavertail_splash 19 hours ago Flag

    well when it only achieved a 2 cent drop in SP it wasn't too bright now was it? At low vol. any such moves would have had a much bigger impact on SP if it wasn't being gamed like GERN. There was someone who bought the entire block 2 cents below the offer. It's called hedge fund ping pong.

  • beavertail_splash beavertail_splash 19 hours ago Flag

    BM unless you forgot there were dozens of law suits launched against the company following the clinical hold news. Doubt any had merit but the damage on SP was significant when you consider it would only take some unscrupulous lobby interest to pay out the $50 fee required to register each of the dozens of suits. Never saw a class action with so many separate firms filing individually. For a measly couple of grand of incurred costs you could wipe out 10's of millions in company public market capital and silence the CEO during the course of these actions. Add to this the FDA's clinical hold coming from left field based on very weak and inconsistent data concerns stemming from completely different trials showing unprecedented efficacy in both ET and MF ranging over a three year period(ET trials). It makes no cents. At least for shareholders.
    Black you bring up valid points but the way you keep ENDLESSLY going on about Chippy and bad management me thinks someone like yourself could easily be behind such efforts. No one knows who really did what but the space is riddled with questions and concerns. Repeating that management is the culprit is only half the story. There are many other possibilities. With so much to gain GERN has attracted competitors like INCY with so much to lose. I'm sure they won't take this lying down. To delay GERN they just extend their profitable market niche offering little efficacy (treats only symptoms of the disease) & high risks wrt toxicity to
    patients with myeloproliferative disorders. Imet on the other hand has shown results in remissions that make it "tantamount to a cure". Interesting to note the latest (newest) brochure from MAYO doesn't even mention INCY's Ruxolitnib as a treatment for MF under their hematological cancer heading. Remissions trump comfort at the MAYO and are supported by latest trial data wrt to ET & MF studies.

  • beavertail_splash beavertail_splash Sep 18, 2014 12:17 AM Flag

    In reference to the cessation of the MF First study, Scarlett said the “decision had nothing to do with liver test abnormalities. That was never discussed and we are unaware of any reason vis-à-vis liver abnormalities that played any role in stopping that study.” - See more at: FDA-Asks-Geron-to-Halt-Imetelstat-Development. Apparently Chippy begs to differ.
    Imetelstat initially garnered attention at the 2012 ASH annual meeting when phase II results were presented for patients with refractory essential thrombocythemia (ET). In the study, patients were treated with weekly intravenous imetelstat. Updated findings from 18 patients with ET were presented in June 2013 at the European Hematology Association (EHA) Congress. At this point, imetelstat elicited a complete response rate of 89% following a median 14-month duration of treatment.
    “We were surprised by these actions,” John “Chip” Scarlett, MD, the president, CEO, and director at Geron, said regarding the verbal notice of the full clinical hold during a webcast conducted following the announcement on March 12.
    “An expert panel of liver experts along with our internal safety staff have periodically reviewed the data and all possible liver-related SAEs [serious adverse events],” Scarlett said. “Our and their conclusions were that the benefit-risk profile of imetelstat was favorable. These conclusions remained consistent as the ET trial progressed.” The FDA slapped this clinical hold a year and a half after the initial ET study results were presented at ASH 2012 and updated last year at ASH 2013. Tell me the FDA knows what they are doing by their actions?

  • beavertail_splash by beavertail_splash Sep 17, 2014 12:46 PM Flag

    The results of a Mayo Clinic study demonstrate that
    a drug named imetelstat induces remissions in some
    patients with myelofibrosis. This is a form of chronic
    leukemia that affects the patient’s bone marrow
    that is replaced by fibrosis (scar tissue) instead
    of blood-producing cells.
    Scientists do not yet know the exact mechanism of
    action for imetelstat, but believe it interferes with the
    survival and proliferation of cancer cells by inhibiting
    a critical enzyme called telomerase. One of the functions
    of telomerase is to repair the ends of chromosomes
    called telomeres, and because cancer cells have shorter
    than normal telomere size, they are particularly susceptible
    to the drug.
    The study results are promising. Some patients
    participating in the clinical trial taking imetelstat obtained
    dramatic responses, and we have seen some complete
    responses (tantamount to a cure), which is almost
    unheard of in this disease.
    STOPPING HEMATOLOGICAL CANCER:
    New Drug Induces Remissions in Myelofibrosis
    Although patients may experience relief in response
    to other treatments, their bone marrow does not
    usually return to normal. But in the case of this new
    therapy, some of the patients participating in the trial
    developed normal bone marrow.
    Researchers studied imetelstat in 33 patients at
    Mayo Clinic and have now followed the first 22 patients
    for more than six months. Among these 22 patients,
    two achieved complete remissions and three partial
    remission, including reversal of bone marrow fibrosis
    in four of the five patients

  • beavertail_splash beavertail_splash Sep 17, 2014 12:38 PM Flag

    some hedge fund backed with deep pockets no doubt standing behind naked with shorts off. Almost thought it was Maine.

  • Reply to

    SEC failure

    by carolyn.whitney26 Sep 16, 2014 10:13 PM
    beavertail_splash beavertail_splash Sep 17, 2014 12:33 PM Flag

    ....like current hedge fund owners don't blatantly lie to investigators and what happens to them? She was made an example of, 5 months for fibbing. She claimed she had not been aware of any impropriety at the time. Maybe she actually thought that. Her broker was not prosecuted. He should have known better.

  • beavertail_splash beavertail_splash Sep 17, 2014 12:16 PM Flag

    The FDA is obviously complicit with the INCY lobby in delaying GERN's progress on MF trials. As per MAYO CLINIC; "The study results are promising. Some patients
    participating in the clinical trial taking imetelstat obtained
    dramatic responses, and we have seen some complete
    responses (tantamount to a cure), which is almost
    unheard of in this disease."
    Irish husbands remission count has been 18 months now and has shown bone marrow healing of scar tissue in his "cured" response. How can they possibly delay this and for what? Jakafi, a toxic oncology 'placebo' has been a failure. JMHeart felt Observatons

  • Reply to

    SEC failure

    by carolyn.whitney26 Sep 16, 2014 10:13 PM
    beavertail_splash beavertail_splash Sep 17, 2014 10:15 AM Flag

    It's an old boys network...she's a girl.

  • Reply to

    PIP is plainly now worth more than $4.11 / share

    by teebrane Sep 16, 2014 1:28 PM
    beavertail_splash beavertail_splash Sep 17, 2014 1:19 AM Flag

    this from SIGA's PR
    "The commencement of the chapter 11 case will prevent PharmAthene from taking any enforcement action at this time and also will permit SIGA's intended appeal to go forward.
    Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer, said, "Enforcement of the expected judgment of the Court of Chancery would threaten SIGA's viability, its ability to produce and deliver our smallpox drug, Tecovirimat, and its critical role in Project BioShield. We remain committed to performing under SIGA's contract with BARDA, obtaining FDA approval for Tecovirimat, and growing our company. SIGA has adequate liquidity to conduct its operations, satisfy all of its contractual commitments, and, with the stay afforded by chapter 11, pursue its appellate rights."
    Doesn't look like something that will be resolved anytime soon. What will PIP ride on in the meantime?

  • beavertail_splash beavertail_splash Sep 17, 2014 12:47 AM Flag

    Honestly if the FDA did make a human error on this hold, I'm sure 6 months would be adequate time to reverse their decision. We haven't seen anything indicating such safety trial issues to warrant such action.

  • Reply to

    HER2-positive Breast Cancer trial still running

    by tazamatic2002 Sep 16, 2014 10:34 AM
    beavertail_splash beavertail_splash Sep 16, 2014 10:41 PM Flag

    BP Imetelstat restoring drug sensitivity as a novel oncology indication would be huge. Great thought/observation....filing that in my IMET Holy Grail folder.

  • beavertail_splash beavertail_splash Sep 16, 2014 10:29 PM Flag

    It's Fartstain...sheeze Louise, some people just can't spell

  • Reply to

    PIP is plainly now worth more than $4.11 / share

    by teebrane Sep 16, 2014 1:28 PM
    beavertail_splash beavertail_splash Sep 16, 2014 7:22 PM Flag

    time for PIP to move on and attemt to create some wealth on their own. This whole process could easily take 2 or more years to resolve if ever. Perelman isn't the negotiating type and would sooner shelve SIGA than see PIP profit from it. Sucks for shareholders but seriously what has PIP done in the last 8 years other than rely on winning this court case for any future income?

  • Reply to

    PIP is plainly now worth more than $4.11 / share

    by teebrane Sep 16, 2014 1:28 PM
    beavertail_splash beavertail_splash Sep 16, 2014 7:14 PM Flag

    ...where that $188M was deployed?
    Weren't there some renovations in east Hampton that needed doing?

  • beavertail_splash beavertail_splash Sep 16, 2014 12:46 PM Flag

    Haven't the hedge funds accumulated enough shares to feed the next run up? I'd press the up button on this elevator but as a beaver I can't reach it.

  • Reply to

    Volume

    by beavertail_splash Sep 16, 2014 11:58 AM
    beavertail_splash beavertail_splash Sep 16, 2014 12:30 PM Flag

    it did bfr the June 13th announcement but the SP action was moving up and shorts were covering. These two elements are missing so far.

  • Reply to

    TRANS TECH PHARMA

    by beavertail_splash Mar 21, 2013 7:44 PM
    beavertail_splash beavertail_splash Sep 16, 2014 12:27 PM Flag

    ...the mystery con-tinues

  • beavertail_splash beavertail_splash Sep 16, 2014 12:22 PM Flag

    still an enigma

  • Didn't they have a pipeline they were working on at one time. Could a private company such as Trans Tech be the net benefactor of this latest action?

  • beavertail_splash by beavertail_splash Sep 16, 2014 11:58 AM Flag

    Volume as of late is looking like it was just bfr. the June 13 partial hold lift news. Hopefully it will be a repeat coming soon with a full lift. Mind you short interest was down then as well.

SIGA
1.41+0.07(+5.22%)10:24 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.